peramivir disappoints in results, page-4

don't get too excited about Biocryst's "failure", it seems that they failed to do a proper intramuscular injection with a lot of the patients by using too short a needle; it was quite effective in the patients where they used a longer needle;

of course this does say something about their poor management of the trial

Zanamivir does have a better resistance profile.

Of course the most disappointing thing is the failure to properly trial IV Zanamivir.

GSK neglected market share so much they have allowed Peramivir a free run without competition. GSK could have pushed this years ago and flu patients could have recieved IV relenza in hospitals for years.